Time-release formulations are associated with the added advantages of convenience of dosing, improved compliance, and less fluctuation in blood levels across the course of the day.

$BCRX In both the SAD and the MAD studies, oral BCX9250 was safe and well tolerated, with no serious adverse events, No safety signals were seen.

Nice and consistent for the median patient FYI the poster this chart is from notes that none of these patients are from the clinical trial

$BCRX so they hit their Q4 numbers, had stellar phase IA results and guided for a 70Mil increase in revenue in 202e.

$BCRX it’s a great time to be a BioCryst shareholder, oooup FDA clinical pause, hey we still have 9250, fda clinical lift, 9250 is too tough, 9930 is too tough…

A trial involving 450 children in Burkina Faso found that three doses of the vaccine, plus a booster shot, were up to 80 percent effective at preventing infection.

BCX10013 pre clinical may be impressive

$BCRX GSK: ANNOUNCES POSITIVE PHASE IIA STUDY RESULTS FOR A NEW FIRST-IN-CLASS CANDIDATE MEDICINE FOR PATIENTS WITH TUBERCULOSIS * GSK - TREATMENT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IDENTIFIED

$BCRX $ATNM $ATNM positive Phase 3 for AML and only 24 million float!!

Management revenue growth product execution Great research team market competitiveness against it's competition size and future growth of market clinical trials BCRX is a 10 on all fronts

$RSLS Nice consolidation phase before this one goes.

$RSLS nice green boom boom after closed offering $FWBI new clinical study news $KPRX $CELZ $ICU

$PBLA multiple phase 3 trail ..price 8 cents ..dirt cheap $KALA $RSLS $ATNF $PTPI

Phase 2/3 is expected to be positive.

$SRNE https://www.youtube.com/watch?v=n6_Ypx6soYQ great product, great clinical results .. expect a new ATH from Scilex this week!

Ji announced favorable phase 3 results in December 2021.

The results have been so good OVYDSO leapt from phase 1 to phase 3.

Also Zero Adverse Effects during Trial 👌.

phase 2/3 ready Each one is a potential all-star.

More then enough to cover SRNE trials for many years.

Sofusa/Enbrel trial was nothing short of incredible 10/10 response is previous NON-RESPONDERS at 50% the previous does.

$SRNE tomorrow great news about CoviMark, Virex, Phase 2 Mpro trial, Semdexa NDA, Abivertinib China/US, MSC trials in US/Brazil, Socazolimab NDA someone bought 1 million shares AH ✅

$SRNE me when we get that positive clinic trials news 😂